AVTR מכפיל מחיר להכנסות עתידי Avantor Corp

Amidst fierce competition for contracts within the pharmaceutical supply oligopoly, the efficiency of Avantor, Inc. (AVTR) is validated by its expected P/S multiple, which remains at 0.90. The fundamentals are supported by R&D in biopharmaceuticals and laboratory automation. High customer loyalty to complex equipment minimizes pricing pressure, ensuring the company's market share stability.

Avantor, Inc. (AVTR) is building a foundation for predictable revenue growth through a stable workforce and expansion into the B2B IT sector. The ratio of current market capitalization to expected sales allows for an assessment of the company's market value relative to its future cash flows. By analyzing the forward P/S multiple, investors can determine whether the asset is overvalued or trading at a discount during the intervals between quarterly reports.